Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics Learn More
Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics Learn More
overview
Veracyte’s genomic tests are setting new standards in cancer and other diseases where they are helping to inform both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. We develop our genomic classifiers using RNA whole-transcriptome sequencing and machine learning to answer specific clinical questions to help improve patient care. All of our tests are covered by Medicare and are used by leading institutions across the United States. The company’s CLIA-certified clinical laboratory is an in-network provider for most of the nation’s major health plans. In December 2019, Veracyte acquired the exclusive global diagnostics rights to the nCounter® FLEX Analysis System through which it plans to make its genomic tests available to physicians and their patients via local laboratories worldwide. Through this transaction, Veracyte also expanded its oncology indications to include breast cancer and lymphoma.
  • Prosigna
    Using prognostic information to inform next steps in patient care
    Learn more  >
  • Afirma
    Reducing unnecessary surgeries and informing treatment decisions in thyroid cancer diagnosis
    Learn more  >
  • Percepta
    Reducing unnecessary invasive procedures and guiding next steps in lung cancer evaluation
    Learn more  >
  • Envisia
    Increasing confidence in idiopathic pulmonary fibrosis diagnosis
    Learn more  >